Summit Therapeutics
Clinical trials sponsored by Summit Therapeutics, explained in plain language.
A biopharmaceutical company developing novel therapies for infectious diseases and cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New lung cancer drug ivonescimab takes on pembrolizumab in major trial
Disease control Recruiting nowThis phase 3 study compares ivonescimab, an experimental immunotherapy, to the standard drug pembrolizumab in 780 people with advanced non-small cell lung cancer that has high PD-L1 levels. Participants receive one of the two drugs as their first treatment. The study measures how…
Phase 3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New immunotherapy combo takes aim at bladder and urinary tract cancers
Disease control Recruiting nowResearchers are testing whether adding ivonescimab to enfortumab vedotin works better than adding pembrolizumab to enfortumab vedotin in people with locally advanced or metastatic urothelial cancer who have not yet received systemic treatment. The trial enrolls about 800 adults w…
Phase 2/3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for advanced colon cancer: experimental drug combo enters phase 3 trial
Disease control Recruiting nowThis phase 3 study tests whether a new drug called ivonescimab, combined with standard chemotherapy (FOLFOX), works better than the current standard treatment (bevacizumab plus FOLFOX) for people with metastatic colorectal cancer that has spread. About 600 adults who have not had…
Phase 3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New immunotherapy combo aims to outperform standard lung cancer treatment
Disease control Recruiting nowThis large Phase 3 trial is testing whether a new immunotherapy drug called ivonescimab, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has spread. The st…
Phase 3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC